Search PubMed⌕ Search

Biomedical subjects

Chang-Jiun Wu

Publications and source records attributed to Chang-Jiun Wu.

4 recordsLinked to original sources
PubMed2026

Artificial intelligence for translational personalized neoantigen cancer vaccine development.

Personalized neoantigen cancer vaccine is a promising strategy for precision immunotherapy by targeting patient-specific and mutation-derived tumor antigens. Early clinical studies have demonstrated the feasibility, safety, and immunogenicity of these vaccines across multiple solid tumors, with encouraging outcomes particularly when combined with immune checkpoint blockade. However, broader clinical translation remains limited by sequential bottlenecks across the vaccine development pipeline, including false-positive neoantigen selection,  imperfect modeling of antigen processing and HLA presentation, limited prediction of T-cell receptor recognition, and challenges in formulation, delivery, and manufacturing. Artificial intelligence and advanced computational workflows are increasingly integrated into this pipeline to improve candidate prioritization and support more reproducible decision-making. In this review, we summarize clinical progress and key translational barriers in personalized neoantigen vaccination, and discuss how AI-enabled approaches may contribute across four major stages: multi-omics integration for neoantigen discovery, processing-aware HLA presentation prediction, structure-aware and TCR-informed immunogenicity modeling, and data-driven formulation optimization, particularly for lipid nanoparticle-based delivery systems. These approaches are able to help narrow biological and chemical search spaces, improve prioritization, and provide mechanistic insights into antigen presentation and immune recognition rather than replacing experimental validation. This articlefurther addresses future implementation challenges, including dataset diversity, model interpretability, prospective benchmarking, manufacturing traceability, and evolving regulatory frameworks for individualized mRNA cancer immunotherapies. Integrating computational innovation with rigorous immunological validation, scalable manufacturing, and regulatory oversight will be essential for advancing personalized neoantigen vaccines toward broader clinical implementation.

Cancer Vaccines↗
PubMed2005

GEMS: a web server for biclustering analysis of expression data.

The advent of microarray technology has revolutionized the search for genes that are differentially expressed across a range of cell types or experimental conditions. Traditional clustering methods, such as hierarchical clustering, are often difficult to deploy effectively since genes rarely exhibit similar expression pattern across a wide range of conditions. Biclustering of gene expression data (also called co-clustering or two-way clustering) is a non-trivial but promising methodology for the identification of gene groups that show a coherent expression profile across a subset of conditions. Thus, biclustering is a natural methodology as a screen for genes that are functionally related, participate in the same pathways, affected by the same drug or pathological condition, or genes that form modules that are potentially co-regulated by a small group of transcription factors. We have developed a web-enabled service called GEMS (Gene Expression Mining Server) for biclustering microarray data. Users may upload expression data and specify a set of criteria. GEMS then performs bicluster mining based on a Gibbs sampling paradigm. The web server provides a flexible and an useful platform for the discovery of co-expressed and potentially co-regulated gene modules. GEMS is an open source software and is available at http://genomics10.bu.edu/terrence/gems/.

Algorithms↗
PubMed2004

Gene expression module discovery using gibbs sampling.

Recent advances in high throughput profiling of gene expression have catalyzed an explosive growth in functional genomics aimed at the elucidation of genes that are differentially expressed in various tissue or cell types across a range of experimental conditions. These studies can lead to the identification of diagnostic genes, classification of genes into functional categories, association of genes with regulatory pathways, and clustering of genes into modules that are potentially co-regulated by a group of transcription factors. Traditional clustering methods such as hierarchical clustering or principal component analysis are difficult to deploy effectively for several of these tasks since genes rarely exhibit similar expression pattern across a wide range of conditions. Bi-clustering of gene expression data is a promising methodology for identification of gene groups that show a coherent expression profile across a subset of conditions. This methodology can be a first step towards the discovery of co-regulated and co-expressed genes or modules. Although bi-clustering (also called block clustering) was introduced in statistics in 1974 few robust and efficient solutions exist for extracting gene expression modules in microarray data. In this paper, we propose a simple but promising new approach for bi-clustering based on a Gibbs sampling paradigm. Our algorithm is implemented in the program GEMS (Gene Expression Module Sampler). GEMS has been tested on synthetic data generated to evaluate the effect of noise on the performance of the algorithm as well as on published leukemia datasets. In our preliminary studies comparing GEMS with other bi-clustering software we show that GEMS is a reliable, flexible and computationally efficient approach for bi-clustering gene expression data.

Cluster Analysis↗